Rivaroxaban for Slow Coronary Flow After PCI in STEMI
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
About this trial
The goal of this clinical trial is to learn if drug Rivaroxaban works to improve slow flow in STEMI patients after PCI in adults. It will also learn about the safety of drug Rivaroxaban. The main questions it aims to answer are:
Does drug Rivaroxaban Reduce the Corrected TIMI Frame Count (cTFC) in 1 Week After PCI ?
Researchers will compare Combination therapy with rivaroxaban (2.5 mg administered twice daily), aspirin (100 mg administered daily), and clopidogrel (75 mg administered daily) to Dual Antiplatelet Therapy to see if drug Combination therapy with rivaroxaban, aspirin works to treat Slow Flow in STEMI Patients After PCI.
Participants will:
Take drug Combination therapy with rivaroxaban (2.5 mg administered twice daily), aspirin (100 mg administered daily), and clopidogrel (75 mg administered daily) or Dual Antiplatelet Therapy every day for 1 months.
Visit the clinic in 7 days、30 days and 365 days for checkups and tests.
Eligibility criteria
Qualifiers
Age ≥ 18 years, regardless of gender;
Patients with ST-segment elevation myocardial infarction (STEMI) (meeting the diagnostic criteria of the 2019 Chinese "Guidelines for the Diagnosis and Treatment of Acute ST-Segment Elevation Myocardial Infarction");
Patients undergoing percutaneous coronary intervention (PCI);
Patients with slow flow after PCI (TIMI flow grade > 0 but < 3);
Disqualifiers
Presence of malignant tumors or diseases with a life expectancy of less than 1 year;
Coagulation disorders, diagnosed or suspected hematological diseases (excluding mild or moderate anemia);
Thrombocytopenia (platelet count < 100 × 10⁹/L); history of severe gastrointestinal diseases or peptic ulcers; active bleeding within the past 3 months or major surgery history; history of intracranial hemorrhage or intracranial aneurysm;
History of cerebral hemorrhage or ischemic stroke within the past 6 months;
Trial design
Treatments tested in this trial
- Dual Antiplatelet (DAPT) Therapy
- Rivaroxaban
Treatment groups
60 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead sponsor
Affiliated Hospital of Jiaxing University
Collaborator
The Second Affiliated Hospital of Jiaxing University
Collaborator
Wenzhou People's Hospital
Collaborator
Source ClinicalTrials.gov